Pharmaceutical company Atlantic Healthcare named John Temperato U.S. president and COO.
Here's what you should know:
1. Mr. Temperato will lead the U.S. commercialization program for the company's inflammatory bowel disease drug, alicaforsen.
2. He comes to Atlantic after serving as Melinta Therapeutics President and COO. He also had a tenure at Salix Pharmaceuticals.
3. Mr. Temperato said, "I am delighted to join Atlantic Healthcare at what is an extremely exciting time. The highly experienced team has deep roots in pharmaceuticals, alicaforsen enema is in the final stages of clinical trials and a promising pipeline is being developed for alicaforsen tablets in additional GI indications."